Inside AbbVie's Post-Humira Playbook: Pipeline Promise Meets Margin Reality

On the surface, AbbVie's revenue looks stable: $56.2 billion in 2021, $58.1 billion in 2022, a dip to $54.3 billion in 2023 as Humira eroded, then recovery to $56.3 billion in 2024 and $61.2 billion in 2025. That $61.2 billion figure — an 8.6% year-over-year increase — is the number management will highlight.

But the composition has shifted dramatically. Humira's contribution has fallen from roughly 37% of revenue to under 15%, while Skyrizi and Rinvoq have ramped to a combined $18-20 billion run rate. The replacement maths technically works. The margin maths does not — at least not yet.

Here's what the headline revenue number conceals. AbbVie's net income collapsed from $11.8 billion in 2022 to $4.9 billion in 2023, and hasn't recovered — sitting at $4.3 billion in 2024 and $4.2 billion in 2025. Revenue went up 9% from 2024 to 2025. Net income went down slightly. That's a red flag.

The profit margin has compressed to 6.9%, down from 20.4% in 2022. Operating margin sits at 34.1%, which looks healthy until you realise it was over 30% even during the worst of the Humira cliff. The gap between operating and net income tells you where the pain is: below the operating line, in interest expense from the $70+ billion in debt accumulated through the Allergan acquisition, and in restructuring charges tied to the portfolio transition.

The historical pattern is well-documented. The pattern is always the same: management promises seamless transitions, Wall Street models linear replacement curves, and reality delivers something messier. AbbVie is following the script precisely.

AbbVie's trailing P/E of 87.7x looks absurd for a pharma company. But the forward P/E of 14.3x tells a completely different story — the Street is modelling a massive earnings recovery. The PEG ratio of 0.49 is the cheapest in big pharma, implying the market expects earnings growth to normalise rapidly.

The question is whether that expectation is realistic. Skyrizi and Rinvoq need to sustain combined growth rates above 25% for the next two years to deliver the earnings the forward multiple assumes. The 340B lawsuit adds regulatory risk to the pricing assumptions underpinning those forecasts. If drug discount programmes expand, the margin compression we've already seen could deepen.

Credit where it's due: AbbVie's replacement drugs are performing well clinically and commercially. Skyrizi in psoriasis and Crohn's disease, and Rinvoq across rheumatoid arthritis, atopic dermatitis, and ulcerative colitis — these are large addressable markets with demonstrated efficacy advantages over older biologics.

The competitive risk comes from the JAK inhibitor class (Rinvoq's category) facing ongoing FDA scrutiny around cardiovascular safety signals. Every boxed warning update is a potential headwind to prescribing volumes. Skyrizi faces fewer competitive threats in the near term, but Eli Lilly's pipeline in immunology is closing fast.

For AbbVie to justify even the forward multiple, three things need to happen simultaneously. Skyrizi needs to cross $15 billion in annual sales by 2027 — achievable based on current trajectory. Rinvoq needs to hold above $10 billion despite JAK inhibitor headwinds — more uncertain. And the broader pipeline, particularly in oncology (post the ImmunoGen acquisition) and neuroscience (the Cerevel deal), needs to deliver at least two blockbuster approvals in the next 18 months.

Management has been aggressive on M&A, spending over $20 billion on pipeline acquisitions in the last two years. The debt load reflects this — total debt exceeds cash by a wide margin. If the pipeline delivers, the leverage was brilliant. If it doesn't, the 3.1% dividend yield becomes the only reason to own the stock.